Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Short summary

Once-weekly exenatide (2 mg) was noninferior to placebo in preventing major adverse cardiovascular events (MACE) in patients with type 2 diabetes, but did not demonstrate superiority. The composite outcome occurred in 11.4% of the exenatide group vs. 12.2% of the placebo group (hazard ratio, 0.91; P=0.06 for superiority) over a median of 3.2 years.

AI-generated from the title and abstract; the full text is not read.